JP2020536854A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536854A5 JP2020536854A5 JP2020517328A JP2020517328A JP2020536854A5 JP 2020536854 A5 JP2020536854 A5 JP 2020536854A5 JP 2020517328 A JP2020517328 A JP 2020517328A JP 2020517328 A JP2020517328 A JP 2020517328A JP 2020536854 A5 JP2020536854 A5 JP 2020536854A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- medicament according
- subject
- semaguruchido
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 20
- 230000002265 prevention Effects 0.000 claims 3
- 230000037221 weight management Effects 0.000 claims 3
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 claims 2
- 229950011186 semaglutide Drugs 0.000 claims 2
- 108010060325 semaglutide Proteins 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002650 habitual effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022112446A JP7475398B2 (ja) | 2017-10-12 | 2022-07-13 | 医学療法におけるセマグルチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17196254 | 2017-10-12 | ||
| EP17196254.1 | 2017-10-12 | ||
| PCT/EP2018/077654 WO2019072941A1 (en) | 2017-10-12 | 2018-10-10 | SEMAGLUTIDE IN MEDICAL THERAPY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022112446A Division JP7475398B2 (ja) | 2017-10-12 | 2022-07-13 | 医学療法におけるセマグルチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536854A JP2020536854A (ja) | 2020-12-17 |
| JP2020536854A5 true JP2020536854A5 (enExample) | 2021-07-29 |
| JP7148605B2 JP7148605B2 (ja) | 2022-10-05 |
Family
ID=60083831
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517328A Active JP7148605B2 (ja) | 2017-10-12 | 2018-10-10 | 医学療法におけるセマグルチド |
| JP2022112446A Active JP7475398B2 (ja) | 2017-10-12 | 2022-07-13 | 医学療法におけるセマグルチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022112446A Active JP7475398B2 (ja) | 2017-10-12 | 2022-07-13 | 医学療法におけるセマグルチド |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US12029779B2 (enExample) |
| EP (1) | EP3694538A1 (enExample) |
| JP (2) | JP7148605B2 (enExample) |
| KR (1) | KR20200069316A (enExample) |
| CN (4) | CN120241968A (enExample) |
| AU (2) | AU2018348929B2 (enExample) |
| BR (1) | BR112020006246A2 (enExample) |
| CA (1) | CA3078652A1 (enExample) |
| CL (1) | CL2020000812A1 (enExample) |
| IL (3) | IL322968A (enExample) |
| MA (1) | MA50358A (enExample) |
| MX (3) | MX2020003049A (enExample) |
| MY (1) | MY204827A (enExample) |
| PH (1) | PH12020550185A1 (enExample) |
| SG (1) | SG11202002841PA (enExample) |
| TW (1) | TWI842681B (enExample) |
| WO (1) | WO2019072941A1 (enExample) |
| ZA (3) | ZA202503350B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200069316A (ko) * | 2017-10-12 | 2020-06-16 | 노보 노르디스크 에이/에스 | 의료 요법에서의 세마글루타이드 |
| PE20230819A1 (es) * | 2020-02-18 | 2023-05-19 | Novo Nordisk As | Composiciones y usos de glp-1 |
| US11478533B2 (en) * | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| EP4313016A4 (en) * | 2021-03-29 | 2025-01-22 | Sanford Health | METHODS AND COMPOSITIONS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES |
| WO2023238017A1 (en) * | 2022-06-08 | 2023-12-14 | Zydus Lifesciences Limited | Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management |
| WO2024249659A2 (en) * | 2023-05-30 | 2024-12-05 | The Medical College Of Wisconsin, Inc. | Methods for weight loss and/or reducing weight gain |
| WO2024252134A1 (en) * | 2023-06-05 | 2024-12-12 | Closed Loop Medicine Ltd | Dosing of incretin pathway drugs |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| DK1412384T3 (da) | 2001-06-28 | 2008-04-28 | Novo Nordisk As | Stabil formulering af modificeret GLP-1 |
| TW200526254A (en) | 2003-09-19 | 2005-08-16 | Novo Nordisk As | Novel GLP-1 derivatives |
| CN104826116A (zh) | 2003-11-20 | 2015-08-12 | 诺沃挪第克公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
| RU2413530C9 (ru) | 2004-11-12 | 2021-05-18 | Ново Нордиск А/С | Стабильные препараты инсулинотропных пептидов |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| AU2006290870B2 (en) | 2005-09-14 | 2013-02-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| KR101438839B1 (ko) | 2006-04-14 | 2014-10-02 | 맨카인드 코포레이션 | 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제 |
| WO2008116088A1 (en) | 2007-03-20 | 2008-09-25 | Nippon Kayaku Kabushiki Kaisha | Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol |
| ES2550363T3 (es) | 2007-09-05 | 2015-11-06 | Novo Nordisk A/S | Derivados truncados de GLP-1 y su uso terapéutico |
| SMT201700189T1 (it) | 2008-12-10 | 2017-05-08 | Glaxosmithkline Llc | Composizioni farmaceutiche di albiglutide |
| MX2011008416A (es) | 2009-02-13 | 2011-09-08 | Boehringer Ingelheim Int | Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos. |
| JP6006118B2 (ja) | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アナログ及び誘導体 |
| CA2797310C (en) | 2010-05-05 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Glp-1 receptor agonist and dpp-4 inhibitor combination therapy |
| WO2012016419A1 (zh) | 2010-08-06 | 2012-02-09 | 浙江贝达药业有限公司 | Glp-1衍生物及其应用 |
| RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
| AR084558A1 (es) | 2010-12-22 | 2013-05-22 | Marcadia Biotech | Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1) |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102718858B (zh) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
| WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| CN102229668A (zh) | 2011-06-03 | 2011-11-02 | 浙江贝达药业有限公司 | 一种glp-1衍生物及其应用 |
| EP2723359A4 (en) | 2011-06-24 | 2015-03-11 | Amylin Pharmaceuticals Llc | METHOD FOR THE TREATMENT OF DIABETES WITH THE HELP OF DELAYED RELEASED FORMULATIONS FROM GLP-1 RECEPTOR AGONISTS |
| WO2013167454A1 (en) | 2012-05-08 | 2013-11-14 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| PL2866825T3 (pl) | 2012-07-01 | 2021-02-22 | Novo Nordisk A/S | <div>ZASTOSOWANIE PEPTYDÓW GLP-1 O PRZEDŁUŻONYM DZIAŁANIU</div> |
| AU2014261336B2 (en) * | 2013-05-02 | 2019-02-28 | Novo Nordisk A/S | Oral dosing of GLP-1 compounds |
| US10294303B2 (en) | 2015-12-23 | 2019-05-21 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists |
| CA3071939A1 (en) | 2017-08-04 | 2019-02-07 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of diabetes and related conditions |
| KR20200069316A (ko) * | 2017-10-12 | 2020-06-16 | 노보 노르디스크 에이/에스 | 의료 요법에서의 세마글루타이드 |
-
2018
- 2018-10-10 KR KR1020207012311A patent/KR20200069316A/ko active Pending
- 2018-10-10 MA MA050358A patent/MA50358A/fr unknown
- 2018-10-10 BR BR112020006246-4A patent/BR112020006246A2/pt not_active Application Discontinuation
- 2018-10-10 AU AU2018348929A patent/AU2018348929B2/en active Active
- 2018-10-10 MX MX2020003049A patent/MX2020003049A/es unknown
- 2018-10-10 WO PCT/EP2018/077654 patent/WO2019072941A1/en not_active Ceased
- 2018-10-10 CN CN202510086779.1A patent/CN120241968A/zh active Pending
- 2018-10-10 CN CN202510084667.2A patent/CN119838000A/zh active Pending
- 2018-10-10 CN CN201880066425.9A patent/CN111212657A/zh not_active Withdrawn
- 2018-10-10 JP JP2020517328A patent/JP7148605B2/ja active Active
- 2018-10-10 IL IL322968A patent/IL322968A/en unknown
- 2018-10-10 CA CA3078652A patent/CA3078652A1/en active Pending
- 2018-10-10 SG SG11202002841PA patent/SG11202002841PA/en unknown
- 2018-10-10 MY MYPI2020001658A patent/MY204827A/en unknown
- 2018-10-10 CN CN202411858188.3A patent/CN119950682A/zh active Pending
- 2018-10-10 EP EP18788709.6A patent/EP3694538A1/en active Pending
- 2018-10-10 IL IL322969A patent/IL322969A/en unknown
- 2018-10-12 TW TW107136028A patent/TWI842681B/zh active
-
2020
- 2020-03-19 MX MX2025002189A patent/MX2025002189A/es unknown
- 2020-03-19 MX MX2025002188A patent/MX2025002188A/es unknown
- 2020-03-20 IL IL273470A patent/IL273470A/en unknown
- 2020-03-27 PH PH12020550185A patent/PH12020550185A1/en unknown
- 2020-03-27 CL CL2020000812A patent/CL2020000812A1/es unknown
- 2020-04-09 US US16/844,552 patent/US12029779B2/en active Active
-
2022
- 2022-07-13 JP JP2022112446A patent/JP7475398B2/ja active Active
-
2024
- 2024-06-07 US US18/736,608 patent/US20240316159A1/en not_active Abandoned
- 2024-08-30 US US18/820,792 patent/US12295988B2/en active Active
-
2025
- 2025-04-09 US US19/174,121 patent/US20250235511A1/en active Pending
- 2025-04-22 ZA ZA2025/03350A patent/ZA202503350B/en unknown
- 2025-04-22 ZA ZA2025/03387A patent/ZA202503387B/en unknown
- 2025-04-22 ZA ZA2025/03388A patent/ZA202503388B/en unknown
- 2025-05-15 AU AU2025203535A patent/AU2025203535A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536854A5 (enExample) | ||
| JP6141958B2 (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| KR101900520B1 (ko) | 복합 조성물 | |
| JP2015187125A5 (enExample) | ||
| RU2008138381A (ru) | Режимы дозирования адреналина | |
| CN115135304A (zh) | Glp-1组合物及其用途 | |
| RU2012148710A (ru) | Органическое соединение для применения при лечении рака печени | |
| JP2018531938A5 (enExample) | ||
| RU2592983C2 (ru) | Комбинированная терапия, включающая вемурафениб и интерферон, для применения в лечении рака | |
| Duems-Noriega et al. | Subcutaneous fluid and drug delivery: safe, efficient and inexpensive | |
| CN101347408B (zh) | 青藤碱静脉输液制剂 | |
| US10821126B2 (en) | Agent for treating retinopathy | |
| JP7291632B2 (ja) | 夜間頻尿治療剤 | |
| BRPI0510895A (pt) | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t | |
| IL307751B1 (en) | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab | |
| WO2011097148A3 (en) | Use of oral heparin preparations to treat urinary tract diseases and conditions | |
| JP2005512946A5 (enExample) | ||
| EA201070557A1 (ru) | Способы и композиции для замедления набора веса, связанного с применением атипичных антипсихотических препаратов | |
| JP2009506043A5 (enExample) | ||
| RU2012126101A (ru) | Полипептидный конъюгат | |
| JP2019535830A5 (enExample) | ||
| US20180289708A1 (en) | Low dose oral dipyridamole compositions and uses thereof | |
| Smith et al. | Pain management, including intrathecal pumps | |
| Park | Novel route of insulin delivery using an implant-mediated drug delivery system | |
| CN108430581A (zh) | 用于利扎曲普坦的药物组合物 |